Merck announced that it has signed a license agreement providing Promega Corp., to Merck's foundational CRISPR intellectual property. Promega will use Merck's CRISPR genome-editing technology to create research products and services, including those for drug development. The agreement will allow researchers to better read the physiological or natural levels of protein expression, which provides a more accurate understanding of protein behavior. Merck intends to continue growing its CRISPR intellectual property portfolio with technologies such as paired Cas9 nickases, which reduce off-target effects, and proxy-CRISPR, which offers researchers more experimental options to accelerate drug development and access to new therapies. Merck holds 22 CRISPR-related patents worldwide covering both methods and compositions, including the fundamental use of CRISPR-Cas9 for genetic integration in mammalian cells. As a user and supplier of genome-editing technology, Merck supports research with genome editing under careful consideration of ethical and legal standards. The company established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing. Merck has also defined a clear operational position considering scientific and societal issues to inform promising therapeutic approaches for use in research and applications.